Keftrum CV Tablet is a combination antibiotic formulation containing Cefuroxime 500 mg and Clavulanic Acid 125 mg, designed to treat a broad spectrum of bacterial infections. Cefuroxime, a second-generation cephalosporin, acts by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefuroxime by preventing enzymatic degradation of the antibiotic by beta-lactamase-producing bacteria. This synergistic combination is effective against various Gram-positive and Gram-negative pathogens, including strains resistant to beta-lactam antibiotics alone. Keftrum CV is indicated for respiratory tract infections such as bronchitis and pneumonia, urinary tract infections, skin and soft tissue infections, otitis media, and sinusitis. It is administered orally and absorbed efficiently, with dosage adjusted based on the severity of infection and patient-specific factors. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypersensitivity reactions are rare but possible. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Proper adherence to prescribed dosage and duration is essential to prevent resistance development. Keftrum CV Tablet represents a reliable therapeutic option in managing bacterial infections requiring broad-spectrum coverage.